Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CRVO

Bayer symbol

Bayer strengthens cell and gene therapy focus with new platform

Platform builds on previous acquisition deals for AskBio and BlueRock

Roche Basel Switzerland

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

First single-dose flu medication approved for post-exposure prophylaxis

- PMLiVE

Novartis and smartpatient launch app experience for wet AMD patients

Wet AMD is the leading cause of severe vision loss and legal blindness in people over the age of 65

Roche Basel Switzerland

Roche’s flu pill Xofluza moves closer towards EU approval

CHMP recommends drug for approval in the EU

- PMLiVE

Novartis’ canakinumab failed to improve survival in COVID-19 study

Swiss pharma company had been studying drug in hospitalised COVID-19 patients

- PMLiVE

Novartis weathers the COVID-19 storm in Q3, lifts outlook

Core operating income increased by 11%, profits from net income drop

Bayer symbol

Bayer pays an initial $2bn for gene therapy firm AskBio

Acquisition will expand Bayers’s pipeline with preclinical/clinical candidates

- PMLiVE

Bayer’s drop of the future

Digital health isn’t always about digital

- PMLiVE

Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses

New developments for COVID-19 treatments and vaccines

- PMLiVE

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

- PMLiVE

Novartis scores CHMP backing for cholesterol drug Leqvio

Potential first-in-class treatment moves closer to EU approval

- PMLiVE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links